Recent NIA meetings, workshops

May 29, 2013

Second Meeting of Reversibility Network, Bethesda, MD – February 26-27, 2013

This meeting explored the applicability of two concepts from the developmental literature to considerations of midlife reversibility of early-established persistent risk mechanisms. The first was the concept of critical periods of plasticity and the potential to reopen these windows later in life. The second was the concept of differential susceptibility to environments and its relevance for intervention approaches beyond early developmental periods. (Contacts: Dr. David Reiss or Dr. Lis Nielsen)

Intervention Testing Program, Bethesda, MD – March 11-12, 2013

The goal of this meeting was to plan the continuation of the Aging Intervention Testing Program (ITP) cooperative agreement program. This workshop brought together experts in aging biology as well as statisticians and clinical trial experts to evaluate the current standard operating procedures. In addition, because the ITP continuation will increase the ability to perform phase 2 studies of health outcomes, several experts in veterinary pathology and healthspan outcome measures also participated in the workshop. (Contact: Dr. Rebecca Fuldner)

Positive Psychobiology Symposium at American Psychosomatic Society, Miami, FL – March 12, 2013

This NIA-funded pre-conference and conference symposium explored approaches to measuring biomarkers related to positive psychological states and functioning. Investigators have recently begun to explore the relationship between positive psychological functioning and physical health. However, our understanding of the underlying mechanisms is still limited. Participants discussed potential positive psychobiological processes that might link positive psychological functioning with enhanced resilience, reduced risk of disease, and improved physical health. (Contact: Dr. Lis Nielsen)

Enabling Partnerships for Alzheimer’s Disease Drug Development, Bethesda, MD – April 10, 2013

This meeting was designed to facilitate the creation of new partnerships aimed at transforming the process of AD drug development into one that is participatory, collaborative, well-integrated, and iterative. The meeting brought together representatives from government, industry, academia, foundations, and patient advocacy groups. The program focused on three interconnected goals: 1) enabling rapid use and reuse of multidimensional data to build predictive models of AD necessary for the development of diagnostics and treatments; 2) creating broad capabilities in quantitative and systems pharmacology to identify and select disease relevant targets, to understand in a precise and predictive manner how drugs impact human pathophysiology and to enable drug repurposing and identification of combination therapies; and 3) expanding the precompetitive space for validation of novel targets from discovery through phase II trials. (Contact: Dr. Suzana Petanceska)

Aging, Cancer and Immunosenescence, Honolulu, HI – May 6, 2013

The Division of Aging Biology (DAB) sponsored a symposium at the annual meeting of the American Association of Immunology. Four speakers gave presentations on their research on the role of inflammation in the development of cancer with aging. Presentations included the role of senescent cells in this process and the challenges of tailoring treatments for elderly cancer patients that have impaired immune system function. (Contact: Dr. Rebecca Fuldner)

Share this:
Email Twitter Linkedin Facebook